

# cefTRIAZONE

BRAND NAME	CEFTRIAZONE AFT, ALPHAPHARM
DRUG CLASS	Cephalosporin antibiotic
AVAILABILITY	Vial contains 0.5 g, 1 g or 2 g of ceftriaxone as ceftriaxone sodium. Each 1 g contains 3.6 mmol of sodium. <sup>1</sup>
WARNING	Contraindicated in patients with severe immediate (IgE mediated) or severe delayed (T-cell mediated) hypersensitivity to penicillins. Seek specialist advice for patients with non-severe immediate hypersensitivity to penicillins.
pH	6–8 when reconstituted <sup>1</sup>
PREPARATION	<p><b>For IM use:</b> Reconstitute the 0.5 g vial with 2 mL and the 1 g vial with 3.5 mL of lidocaine 1%.<sup>1</sup> Reconstitute to 350 mg/mL for IM use in children.<sup>2</sup> (For the AFT 1 g vial use 2.3 mL) Solutions reconstituted with lidocaine must not be injected intravenously.<sup>1</sup></p> <p><b>For IV use:</b> Reconstitute the 0.5 g vial with 5 mL of water for injections and the 1 g vial with 10 mL of water for injections.<sup>1</sup> Reconstitute the 2 g vial with 40 mL of a compatible infusion fluid.<sup>1</sup> For the urgent treatment of critically unwell patients (e.g. sepsis), reconstitute the 2 g vial with 20 mL of water for injections or sodium chloride 0.9%.<sup>3</sup> Powder volume (AFT brand) 1 g – 0.6 mL 2 g – 1.1 mL<sup>4</sup> The solution is slightly opalescent and light yellow to amber. The solution may darken with storage but can still be used.<sup>1</sup></p>
STABILITY	<p>Vial: store below 25 °C. Protect from light.<sup>1</sup> Reconstituted solution: stable for 6 hours below 25 °C and 24 hours at 2 to 8 °C.<sup>1</sup> Infusion solution: stable for 24 hours below 25 °C and 24 hours at 2 to 8 °C.<sup>5</sup> For CoPAT: solutions up to 40 mg/mL are stable for 24 hours at 25 °C.<sup>6,7</sup> There is no information about stability above 25 °C. Infusion solutions prepared in a sterile production unit are stable for more than 7 days at 2 to 8 °C.<sup>5</sup></p>
ADMINISTRATION	
<b>IM injection</b>	Inject into the gluteal muscle. <sup>1</sup> The ventrogluteal site is preferred. If the dose is more than 1 g divide between the left and right sides. <sup>1</sup>
<b>SUBCUT injection</b>	Not recommended
<b>IV injection</b>	For doses up to 1 g, inject over 2 to 4 minutes. <sup>1</sup> Give doses of more than 1 g by IV infusion. In the urgent treatment of critically unwell patients (e.g. sepsis), a 2 g dose can be injected over 5 minutes. <sup>3</sup> See SPECIAL NOTES
<b>IV infusion</b>	Dilute the dose in approximately 40 mL of a compatible fluid and infuse over at least 30 minutes. <sup>1</sup> See SPECIAL NOTES
<b>IV use for infants and children</b>	Dilute to 40 mg/mL or weaker and infuse over 30 minutes. May be diluted to 40 mg/mL and injected over 5 minutes. <sup>1,2</sup> See SPECIAL NOTES

## COMPATIBILITY

- Fluids** Glucose 5%<sup>1</sup>, glucose 10%<sup>1</sup>, glucose in sodium chloride solutions<sup>1</sup>, mannitol 10%<sup>5</sup>, sodium chloride 0.9%<sup>1</sup>
- Y-site** Aciclovir<sup>5</sup>, amifostine<sup>5</sup>, anidulafungin<sup>5</sup>, atracurium<sup>8</sup>, aztreonam<sup>5,8</sup>, bivalirudin<sup>5</sup>, buprenorphine<sup>8</sup>, ciclosporin<sup>8</sup>, cisatracurium<sup>5</sup>, defibrotide<sup>9</sup>, dexamethasone<sup>8</sup>, dexmedetomidine<sup>5</sup>, digoxin<sup>8</sup>, dopamine<sup>8</sup>, ephedrine sulfate<sup>8</sup>, erythromycin<sup>8</sup>, esmolol<sup>8</sup>, fentanyl<sup>8</sup>, foscarnet<sup>5</sup>, furosemide<sup>8</sup>, glyceryl trinitrate<sup>8</sup>, granisetron<sup>5</sup>, heparin sodium<sup>8</sup>, hydrocortisone sodium succinate<sup>8</sup>, insulin (Novorapid)<sup>10</sup>, lidocaine<sup>8</sup>, methylprednisolone sodium succinate<sup>8</sup>, metoclopramide<sup>8</sup>, midazolam<sup>8</sup>, morphine sulfate<sup>5,8</sup>, noradrenaline (norepinephrine)<sup>8</sup>, paracetamol<sup>5</sup>, pethidine<sup>5</sup>, potassium chloride<sup>8</sup>, ranitidine<sup>8</sup>, remifentanyl<sup>5</sup>, sodium bicarbonate<sup>8</sup>, sodium nitroprusside<sup>8</sup>, suxamethonium<sup>8</sup>, tigecycline<sup>5</sup>, verapamil<sup>8</sup>, zidovudine<sup>5</sup>

## INCOMPATIBILITY

- Fluids** Solutions that contain calcium e.g. Hartmann's and Ringer's, parenteral nutrition.<sup>1</sup>  
See SPECIAL NOTES
- Drugs** Aminoglycosides: amikacin, gentamicin, tobramycin<sup>1,5</sup>, aminophylline<sup>5</sup>, azathioprine<sup>11</sup>, azithromycin<sup>5</sup>, calcium chloride<sup>5</sup>, calcium folinate<sup>11</sup>, calcium gluconate<sup>5</sup>, capreomycin<sup>11</sup>, caspofungin<sup>5</sup>, clindamycin<sup>11</sup>, dobutamine<sup>11</sup>, filgrastim<sup>5</sup>, fluconazole<sup>1,5</sup>, ganciclovir<sup>11</sup>, haloperidol lactate<sup>11</sup>, hydralazine<sup>11</sup>, imipenem-cilastatin<sup>11</sup>, isavuconazole<sup>5</sup>, labetalol<sup>5</sup>, linezolid<sup>1</sup>, magnesium sulfate<sup>8</sup>, mycophenolate mofetil<sup>11</sup>, pentamidine<sup>5</sup>, promethazine<sup>11</sup>, protamine<sup>11</sup>, sodium ascorbate<sup>11</sup>

## SPECIAL NOTES

Do not mix ceftriaxone with IV solutions that contain calcium because a precipitate can form. Deaths have been reported in neonates. Ceftriaxone is contraindicated in neonates receiving IV calcium-containing solutions. In other age groups, ceftriaxone must not be administered at the same time as IV calcium-containing products but may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid.<sup>5</sup>

## REFERENCES

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 03/10/2019.
2. Phelps S, Hagemann TM, Lee KR, Thompson AJ. Pediatric injectable drugs. 11th ed. Bethesda, MD: Am Soc Health-System Pharmacists; 2018.
3. Marsh K, Ahmed N, Decano A, Dubrovskaya Y, Shin-Pung J, Siegfried J, et al. Safety of intravenous push administration of beta-lactams within a healthcare system. *Am J Health-Syst Pharm* 2020; 77: 701-8
4. Quality assurance. Displacement values [email]. Auckland, NZ: AFT Pharmaceuticals; 30/10/2019.
5. McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
6. Allen LV, Stiles ML, Prince SJ, Smeeding J. Stability of 14 drugs in the latex reservoir of an elastomeric infusion device. *Am J Health-Syst Pharm* 1996; 15: 2740-3.
7. Walker SE, Lazetta J, Law S, Biniecki K. Stability of commonly used antibiotic solutions in an elastomeric infusion device. *Can J Hosp Pharm* 2010; 63(3): 212-24.
8. Trissel LA, Leissing NC. Trissel's Tables of physical compatibility. Lake Forest IL: Multimatrix; 1996.
9. Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. *Am J Health-Syst Pharm* 2014; 71: 1288-91.
10. Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. *Eur J Hosp Pharm* 2015; 22: 123-4.
11. Ceftriaxone. In: IV index. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Greenwood Village, CO: Truven Health Analytics. Accessed 23/08/2019.